OmniAb Investor Conference Presentation Deck

Zimberelimab THE FIRST APPROVED OMNIRAT-DERIVED ANTIBODY • In August of 2021, zimberelimab (GLS-010), an OmniAb-derived fully human anti-PD-1 mAb, was approved in China for the treatment of recurrent or refractory classical Hodgkin's lymphoma Marked the first approval of an OmniAb-derived mAb - ● gloria ARCUS BIOSCIENCES BIOSCIENCES • In 2015, Gloria Bio contracted with Wuxi Biologics to discover and develop zimberelimab in China, using OmniRat - - - Zimberelimab entered clinic in March 2017, and NDA was submitted to China NMPA in February 2020 GloriaBio is also conducting trials in advanced solid tumors, and was granted Breakthrough Therapy designation for the treatment of patients with recurrent/metastatic cervical cancer Zimberelimab is being developed by Arcus Biosciences (in collaboration with Gilead) in North America, Europe, Japan and certain other territories through a 2017 agreement - Arcus is conducting Phase 2 and 3 clinical trials investigating zimberelimab as part of combination therapy in lung, prostate, colorectal, pancreatic and Gl cancers 41 OmniAb

View entire presentation